CLINICAL_TRIALS
trial_result
· 2024-11-27
Clinical Trial Update: Durvalumab Plus Chemotherapy in ES-SCLC (Oriental) [Phase 3]
Summary
A Phase 3 trial of durvalumab plus chemotherapy in extensive-stage small cell lung cancer has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AstraZeneca | Conditions: Small Cell Lung Carcinoma Extensive Disease | Phase 3 | Status: COMPLETED | Results posted: 2024-11-27